THOR, CONTACT-03, and Other Advances in GU Cancers at ASCO23

THOR, CONTACT-03, and Other Advances in GU Ca...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Suivant

Personalizing Treatment in Head and Neck Cancers

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different ...  Afficher plus

 . 20min 51sec
Can Low-Dose Immunotherapy Expand Global Access to Cancer Care?

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducin ...  Afficher plus

 . 14min 53sec

Épisodes Recommandés

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ...  Afficher plus

 . 14min 9sec
Podcast 300: NADIM II trial offers “quite exciting” results in lung cancer
Clinical Conversations

A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE.

We’re back with another interview from this year’s IASLC conference.

This time, Christine Sadlowski and Dr. Julia Rotow interview Dr. Mar ...

  Afficher plus

 . 9min 32sec
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.1 Part 1
ASCO Guidelines

Dr. Dwight Owen is back on the ASCO Guidelines podcast, discussing the latest updates to the ASCO living guidelines for stage IV NSCLC. In Part 1, Dr. Owen presents the update for stage IV NSCLC without driver alterations. He reviews new evidence from EMPOWER-Lung3 and POSEIDON a ...  Afficher plus

 . 11min 24sec
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer – CDK4/6 Inhibitors Rapid Update
ASCO Guidelines

Dr. Rachel Freedman and Dr. Sharon Giordano share the latest rapid guideline update from ASCO on the adjuvant use of the CDK4/6 inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer. They share details on the impetus for the update, supporting evid ...  Afficher plus

 . 11min 23sec